|[March 07, 2014]
BioLineRx Closes $24.1 Million Underwritten Public Offering of its American Depositary Shares
JERUSALEM --(Business Wire)--
BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage
biopharmaceutical company dedicated to identifying, in-licensing and
developing promising therapeutic candidates, today announced that it has
closed its previously announced underwritten public offering of
9,660,000 American Depositary Shares ("ADSs"), each representing ten
(10) of its Ordinary Shares, at a public offering price of $2.50 per
ADS, for gross proceeds of approximately $24.1 million. All of the ADSs
in the offering were sold by BioLineRx. The amount of ADSs sold includes
an additional 1,260,000 ADSs purchased by the underwriters pursuant to
the over-allotment option granted to them by BioLineRx.
Roth Capital Partners acted as sole book-running manager for the
offering. Maxim Group LLC acted as co-manager.
The ADSs were issued pursuant to a shelf registration statement that was
previously filed with, and declared effective by, the Securities and
Exchange Commission (SEC (News - Alert)). A final prospectus supplement related to the
offering will be filed with the SEC and will be available on the SEC's
website located at www.sec.gov.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction. Any offer, if at al, will be made only by means of a
prospectus supplement and accompanying prospectus forming a part of the
effective registration statement, copies of which may be obtained, when
available, from Roth Capital Partners, 888 San Clemente, Newport Beach,
CA (News - Alert) 92660, (800) 678-9147.
BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company
dedicated to identifying, in-licensing and developing promising
therapeutic candidates. The Company in-licenses novel compounds
primarily from academic institutions and biotech companies based in
Israel, develops them through pre-clinical and/or clinical stages, and
then partners with pharmaceutical companies for advanced clinical
development and/or commercialization.
BioLineRx's current portfolio consists of a variety of clinical and
pre-clinical projects, including: BL-1040 for prevention of pathological
cardiac remodeling following a myocardial infarction, which has been
out-licensed to Bellerophon BCM (f/k/a Ikaria) and is in the midst of a
pivotal CE-Mark registration trial; BL-8040 for treating acute myeloid
leukemia (AML) and other hematological indications, which is in the
midst of a Phase 2 study; BL-7010 for celiac disease, which is in the
midst of a Phase 1/2 study; and BL-5010 for non-surgical removal of skin
lesions, which is expected to commence a pivotal CE-mark registration
trial in the first half of 2014.
For more information on BioLineRx, please visit www.biolinerx.com
or download the investor relations mobile device app, which allows users
access to the Company's SEC documents, press releases, and events.
BioLineRx's IR app is available on the iTunes App Store as well as the
Google (News - Alert) Play Store.
Various statements in this release concerning BioLineRx's future
expectations constitute "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. These
statements include words such as "may," "expects," "anticipates,"
"believes," and "intends," and describe opinions about future events.
These forward-looking statements involve known and unknown risks and
uncertainties that may cause the actual results, performance or
achievements of BioLineRx to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Some of these risks are: changes in
relationships with collaborators; the impact of competitive products and
technological changes; risks relating to the development of new
products; and the ability to implement technological improvements. These
and other factors are more fully discussed in the "Risk Factors" section
of BioLineRx's most recent annual report on Form 20-F filed with the
Securities and Exchange Commission on March 12, 2013. In addition, any
forward-looking statements represent BioLineRx's views only as of the
date of this release and should not be relied upon as representing its
views as of any subsequent date. BioLineRx does not assume any
obligation to update any forward-looking statements unless required by
[ Back To TMCnet.com's Homepage ]